Adoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its
immune-oncology pipeline over the last years. This is in great part due to the recent …

Chimeric antigen receptor (CAR) T cells are a cancer immunotherapy of extremes.
Unprecedentedly effective, but complex and costly to manufacture, they are not yet a …

Cell therapy has revolutionized the treatment of various diseases, such as cancers, genetic
disorders, and autoimmune diseases. Currently, most cell therapy products rely on ex vivo …

Chimeric antigen receptor T cell (CAR-T cell) therapy has shown impressive success in the
treatment of hematological malignancies, but the systemic toxicity and complex …

Background Non-small cell lung cancer (NSCLC) is a worldwide health threat with high
annual morbidity and mortality. Chemotherapeutic drugs such as paclitaxel (PTX) have been …

Cancer is becoming increasingly understood not only as a disease of pathological cells but
also as one of immune hypofunction. The heterogenous and patient-specific nature of …

Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative
potential and become a critical component in the array of B-cell malignancy treatments …

Chimeric antigen receptor (CAR)‐T cell immunotherapy is approved in the treatment of
hematological malignancies, but remains far from satisfactory in solid tumor treatment due to …

Chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as a highly efficacious
treatment modality for refractory and relapsed hematopoietic malignancies in recent years …

Adoptive T cell therapy has demonstrated great promise for treating cancer and other
diseases. While extensive effort has been made to improve ex vivo expansion of T cells …